3152 – Comparison between Time-Limited, Venetoclax-Based and Continuous Bruton Thyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): a Systematic Review and Network Meta-Analysis

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Stefano Molica
Presentation Date: December 7, 2020
Abstract Number: 3152

3140 – Acalabrutinib Vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Ascend Final Results

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Paolo Ghia
Presentation Date: December 7, 2020
Abstract Number: 3140

2216 – Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Matthew S. Davids
Presentation Date: December 6, 2020
Abstract Number: 2216

3146 – Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Jennifer R. Brown
Presentation Date: December 7, 2020
Abstract Number: 3146

2223 – Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Seema A Bhat
Presentation Date: December 6, 2020
Abstract Number: 2223

1317 – Adverse Events in Clinical Trials of Ibrutinib and Acalabrutinib for B-Cell Lymphoproliferative Disorders: A Systematic Review and Network Meta-Analysis

Oral and Poster Abstracts
© 2020 American Society of Hematology. All rights reserved.
Meeting: 62nd ASH® Annual Meeting & Exposition
Presenter: Talal Hilal
Presentation Date: December 5, 2020
Abstract Number: 1317

Expert Interview with Thomas Nösslinger

Expert interview
© 2020 Springer Healthcare Limited.

The following video was produced by Springer Healthcare and is provided courtesy of AstraZeneca. It has not been reviewed by ASH and does not necessarily represent the opinion of ASH.
Interviewee: Thomas Nösslinger
Affiliations(s): 3rd Medical Department, Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria
Disclosures: Honoraria: Janssen, Roche, Gilead, AstraZeneca, Abbvie; Scientific Advisory Board: Janssen, Roche, AstraZeneca, Abbvie
Interview Date: December 10, 2020
Related Abstract(s): 2216, 3140, 3152

Expert Interview with Philipp Staber

Expert interview
© 2020 Springer Healthcare Limited.

The following video was produced by Springer Healthcare and is provided courtesy of AstraZeneca. It has not been reviewed by ASH and does not necessarily represent the opinion of ASH.
Interviewee: Philipp Staber
Affiliations(s): University Clinic of Internal Medicine I, Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
Disclosures: Research Support: Takeda-Millenium, Roche Diagnostics; Honoraria: Amgen, Roche, Janssen, Gilead, Karyopharm, Morphosys, CTI, BMS, Abbvie, Takeda, Beigene, AstraZeneca, Incyte; Scientific Advisory Board: Amgen, Roche, Janssen, Gilead, Karyopharm, Morphosys, CTI, BMS, Abbvie, Takeda, AstraZeneca, Incyte
Interview Date: December 9, 2020
Related Abstract(s): 3146, 1317, 2223

Disclaimer

This content was selected by and is provided to you courtesy of AstraZeneca.

The information provided here includes details of indications that may be off-label and are for scientific medical exchange purposes only. AstraZeneca does not, under any circumstances, promote its products for off-label or unapproved uses.

If you have any questions or want further information, please contact us by phone from Monday to Thursday from 08:00 to 16:30 and Friday from 08:00 to 14:30 at +43 (0) 1 / 711-31-0 or at info.at@astrazeneca.com.

Further information on these drugs can be found here: Acalabrutinib

Report an Adverse Event

All pharmacologically effective drugs have benefits and risks. A risk may be insignificant or acceptable in relation to the therapeutic effect of the drug. Constant monitoring of the safety of a drug throughout the life cycle helps ensure that risks and benefits remain acceptable.

AstraZeneca is committed to ensuring the safety of patients receiving our products.

Adverse events can be reported here.

Fachkurzinformation

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinfomation.

BEZEICHNUNG DES ARZNEIMITTELS: Calquence 100 mg Hartkapseln. Pharmakotherapeutische Gruppe: Antineoplastische Mittel, Proteinkinase-Inhibitoren. ATC Code: L01XE51. QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Jede Hartkapsel enthält 100 mg Acalabrutinib. Sonstige Bestandteile: Kapselinhalt: Mikrokristalline Cellulose, Hochdisperses Siliciumdioxid, Vorverkleisterte Stärke (Mais), Magnesiumstearat (E470b), Poly(Ocarboxymethyl)stärke-Natriumsalz. Kapselhülle: Gelatine, Titandioxid (E171), Eisen(III)-oxid-hydroxid x H2O (E172), Indigocarmin (E132). Drucktinte: Schellack, Eisen(II,III)-oxid (E172), Propylenglycol (E1520), Ammoniak-Lösung. ANWENDUNGSGEBIETE: Calquence als Monotherapie oder in Kombination mit Obinutuzumab ist zur Behandlung von erwachsenen Patienten mit nicht vorbehandelter chronischer lymphatischer Leukämie (CLL) indiziert. Calquence als Monotherapie ist zur Behandlung von erwachsenen Patienten mit chronischer lymphatischer Leukämie (CLL) indiziert, die mindestens eine Vorbehandlung erhalten haben. GEGENANZEIGEN: Überempfindlichkeit gegen den Wirkstoff oder einen der in Abschnitt 6.1 der Fachinformation genannten sonstigen Bestandteile. INHABER DER ZULASSUNG: AstraZeneca AB, SE-151 85 Södertälje, Schweden. REZEPTPFLICHT/APOTHEKENPFLICHT: Rezept- und apothekenpflichtig, wiederholte Abgabe verboten. STAND DER INFORMATION: 11/2020.

Informationen zu den Abschnitten besondere Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstige Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit, Nebenwirkungen sowie den Gewöhnungseffekten sind der veröffentlichten Fachinformation (z. B. Austria Codex) zu entnehmen.

ASH Disclaimer

© 2020 American Society of Hematology. All rights reserved. ASH® and the ASH logo are registered trademarks of the American Society of Hematology. Used with permission.

This content is provided for informational purposes and personal use only, and is not intended to provide medical advice, diagnosis, or treatment or for commercial use. The ideas and opinions expressed herein do not necessarily reflect those of the American Society of Hematology (ASH). The mention of any product, service or therapy in this collection of materials should not be construed as an endorsement of the products mentioned.

The expert interviews appearing herein were not prepared or reviewed by ASH and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASH. ASH assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.